SOX2 and gastric cancer: After GRg3 treatment, the expression of apoptosis-related genes, which target SOX2 and the PI3K/AKT/mTOR signaling pathway, was upregulated in gastric cancer cells, cell migration was significantly inhibited, GRg3 alleviated the drug resistance of gastric cancer cells, and sensitivity to cisplatin was enhanced (13).